MFMárcia Faria

Márcia Faria

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Márcia Faria has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adherens Junction Integrity Is a Critical Determinant of Sodium Iodide Symporter Residency at the Plasma Membrane of Thyroid Cells

    by Márcia Faria, José Vareda, Micaella Miranda, Maria João Bugalho, Ana Luísa Silva, Paulo Matos

    While most cases of differentiated thyroid carcinoma (DTC) are associated with a good prognosis, a significant number progress to advanced disease exhibiting aggressive clinical characteristics and often becoming refractory to radioactive iodine (RAI) treatment, the current gold-standard therapeutic option for metastatic disease. RAI-refractoriness is caused by defective functional expression of the sodium-iodide symporter (NIS), which is responsible for the active transport of iodide across the plasma membrane (PM) into thyroid follicles. NIS deficiency in these tumors often reflects a transcriptional impairment, but also its defective targeting and retention at the cells’ PM. Using proteomics, we previously characterized an intracellular signaling pathway derived from SRC kinase that acts through the small GTPase RAC1 to recruit and bind the actin-anchoring adaptor EZRIN to NIS, regulating its retention at the PM of both non-transformed and cancer thyroid cells. Here, we describe how by reanalyzing the proteomics data, we identified cell–cell adhesion as the molecular event upstream the pathway involved in the anchoring and retention at the PM. We show that by interacting with NIS at the PM, adherens junction (AJ)-associated P120-catenin recruits and is phosphorylated by SRC, allowing it to recruit RAC1 to the complex. This enables SRC-phosphorylated VAV2 exchange factor to activate RAC1 GTPase, inducing NIS retention at the PM, thus increasing its abundance and function at the surface of thyroid cells. Our findings indicate that the loss of epithelial cell–cell adhesion may contribute to RAI refractoriness, indicating that in addition to stimulating NIS expression, successful resensitization therapies might require the employment of agents that improve cell–cell adhesion and NIS PM retention in refractory TC cells.


  • Open Access

    MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells

    by Márcia Faria, Rita Domingues, Maria João Bugalho, Paulo Matos, Ana Luísa Silva

    The Sodium/Iodide Symporter (NIS) is responsible for the active transport of iodide into thyroid follicular cells. Differentiated thyroid carcinomas (DTCs) usually preserve the functional expression of NIS, allowing the use of radioactive iodine (RAI) as the treatment of choice for metastatic disease. However, a significant proportion of patients with advanced forms of TC become refractory to RAI therapy and no effective therapeutic alternatives are available. Impaired iodide uptake is mainly caused by the defective functional expression of NIS, and this has been associated with several pathways linked to malignant transformation. MAPK signaling has emerged as one of the main pathways implicated in thyroid tumorigenesis, and its overactivation has been associated with the downregulation of NIS expression. Thus, several strategies have been developed to target the MAPK pathway attempting to increase iodide uptake in refractory DTC. However, MAPK inhibitors have had only partial success in restoring NIS expression and, in most cases, it remained insufficient to allow effective treatment with RAI. In a previous work, we have shown that the activity of the small GTPase RAC1 has a positive impact on TSH-induced NIS expression and iodide uptake in thyroid cells. RAC1 is a downstream effector of NRAS, but not of BRAF. Therefore, we hypothesized that the positive regulation induced by RAC1 on NIS could be a relevant signaling cue in the mechanism underlying the differential response to MEK inhibitors, observed between NRAS- and BRAF-mutant tumors. In the present study, we found that the recovery of NIS expression induced through MAPK pathway inhibition can be enhanced by potentiating RAC1 activity in thyroid cell systems. The negative impact on NIS expression induced by the MAPK-activating alterations, NRAS Q61R and BRAF V600E, was partially reversed by the presence of the MEK 1/2 inhibitors AZD6244 and CH5126766. Notably, the inhibition of RAC1 signaling partially blocked the positive impact of MEK inhibition on NIS expression in NRAS Q61R cells. Conversely, the presence of active RAC1 considerably improved the rescue of NIS expression in BRAF V600E thyroid cells treated with MEK inhibitors. Overall, our data support an important role for RAC1 signaling in enhancing MAPK inhibition in the context of RAI therapy in DTC, opening new opportunities for therapeutic intervention.


  • Impact of RAC1/1b signalling on Sodium Iodide symporter regulation

    by Marcia Faria, Paulo Matos, Maria Joao Bugalho, Ana Luisa Silva

    The Sodium Iodide Symporter (NIS) is responsible for active transport of iodide into thyroid cells. Its expression in thyroid tumors allows the use of radioactive iodine (131I) as co-adjuvant therapeutic tool to eliminate remaining tumor cells and metastases after total thyroidectomy. Nevertheless, certain subsets of patients with advanced forms of thyroid cancer lose the ability to respond to radioiodine therapy, which drastically reduces their survival rates. Recent studies have implicated the Rac1/p38 pathway in the stimulation of NIS expression through a mechanism that remains unclear. Additionally, the overexpression of RAC1b, a hyperactive splicing variant of RAC1, was recently shown to be overexpressed in a subset of papillary thyroid carcinomas carrying the activating mutation BRAFV600E and to be associated with unfavorable outcome. BRAFV600E mutation, in turn, has been associated with the downregulation of NIS. Here, we further investigate the role of RAC1/RAC1b on NIS expression levels, and developed new cellular models to functionally assess the impact of these GTPases on NIS-mediated iodide uptake. To evaluate whether RAC1b has a role in NIS expression modulation, we determined NIS transcript levels in a cohort of 64 follicular cell-derived thyroid tumors, comparing tumors presenting RAC1b overexpression (n=32) to those that did not (n=32). RAC1b-overexpressing tumors were defined as those with expression levels above a defined threshold (corresponding to the mean value plus two SDs of RAC1b expression level in a normal thyroid group). RAC1b and NIS expression was assessed by quantitative RT-PCR. We found that samples negative for RAC1b expression presented higher levels of NIS in comparison to RAC1b-overexpressing samples (4.402±1.271 vs 1.916±0.5423, respectively; P=0.0384, two-tailed Student’s t-test). Thus, our results show an inverse correlation between RAC1b and NIS expression levels, suggesting that RAC1b might antagonize RAC1 effectiveness at stimulating NIS expression. To further explore the impact of RAC1/1b signalling on NIS expression regulation, we established a halide-sensitive YFP-based reporter in a normal thyroid cell line system, allowing us to detect differences on iodide influx upon TSH stimulation. Our preliminary results support the relevance of further studying the impact of RAC1/1b on NIS regulation.

  • Open Access

    RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells

    by Márcia Faria, Paulo Matos, Teresa Pereira, Rafael Cabrera, Bruno A Cardoso, Maria João Bugalho, Ana Luísa Silva

    Overexpression of tumor-associated RAC1b has been recently highlighted as one of the most promising targets for therapeutic intervention in colon, breast, lung and pancreatic cancer. RAC1b is a hyperactive variant of the small GTPase RAC1 and has been recently shown to be overexpressed in a subset of papillary thyroid carcinomas associated with unfavorable outcome. Using the K1 PTC derived cell line as an in vitro model, we observed that both RAC1 and RAC1b were able to induce a significant increase on NF-kB and cyclin D1 reporter activity. A clear p65 nuclear localization was found in cells transfected with RAC1b-WT, confirming NF-kB canonical pathway activation. Consistently, we observed a RAC1b-mediated decrease in IκBα (NF-kB inhibitor) protein levels. Moreover, we show that RAC1b overexpression stimulates G1/S progression and protects thyroid cells against induced apoptosis, the latter through a process involving the NF-kB pathway. Present data support previous findings suggesting an important role for RAC1b in the development of follicular cell-derived thyroid malignancies and point out NF-kB activation as one of the molecular mechanisms associated with the pro-tumorigenic advantage of RAC1b overexpression in thyroid carcinomas.


  • Open Access

    Extending the Impact of RAC1b Overexpression to Follicular Thyroid Carcinomas

    by Márcia Faria, Liliana Capinha, Joana Simões-Pereira, Maria João Bugalho, Ana Luísa Silva

    RAC1b is a hyperactive variant of the small GTPase RAC1 known to be a relevant molecular player in different cancers. Previous studies from our group lead to the evidence that its overexpression in papillary thyroid carcinoma (PTC) is associated with an unfavorable prognosis. In the present study, we intended to extend the analysis of RAC1b expression to thyroid follicular neoplasms and to seek for clinical correlations. RAC1b expression levels were determined by RT-qPCR in thyroid follicular tumor samples comprising 23 follicular thyroid carcinomas (FTCs) and 33 follicular thyroid adenomas (FTAs). RAC1b was found to be overexpressed in 33% of carcinomas while no RAC1b overexpression was documented among follicular adenomas. Patients with a diagnosis of FTC were divided into two groups based on longitudinal evolution and final outcome. RAC1b overexpression was significantly associated with both the presence of distant metastases (P= 0.01) and poorer clinical outcome (P= 0.01) suggesting that, similarly to that previously found in PTCs, RAC1b overexpression in FTCs is also associated with worse outcomes. Furthermore, the absence of RAC1b overexpression in follicular adenomas hints its potential as a molecular marker likely to contribute, in conjunction with other putative markers, to the preoperative differential diagnosis of thyroid follicular lesions.


  • Prevalence of Leptospira antibodies in wild boars (Sus scrofa) from Northern Portugal: risk factor analysis

    by H. M. Vale-Gonçalves, J. A. Cabral, M. C. Faria, M. Nunes-Pereira, A. S. Faria, O. Veloso, M. L. Vieira, N. Paiva-Cardoso

    SUMMARY: Leptospirosis is a zoonosis of worldwide distribution, caused by infection with pathogenic spirochaetes of the genus Leptospira. The wild boar (Sus scrofa), an important hunting species in Europe, seems to play a significant role in the epidemiological cycle of leptospirosis. A total of 101 serum samples from wild boar hunted in Northern Portugal were analysed for leptospiral antibodies detection by microscopic agglutination test. Sera were collected during hunting seasons (2011–2013) and tested with 17 different pathogenic serovars of Leptospira. Antibodies against nine serovars were detected in 66 (65·4%) of these sera. Serovars Tarassovi and Altodouro exhibited the highest seroreactivity rates (23·8% and 16·8%, respectively), followed by Autumnalis (7·9%) and Bratislava (6·9%). Age and district of origin were found to be risk factors for the presence of leptospiral antibodies in contrast to gender. From a One Health perspective, this study revealed that wild boar should be considered as a potential source of leptospirosis dissemination for humans and animal species (domestic and wild) in shared environments, particularly in the Trás-os-Montes region.